NCT00269893View on ClinicalTrials.gov

A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-platelet Therapy, in Patients Undergoing High-risk Coronary Angioplasty

PHASE3CompletedINTERVENTIONAL
Enrollment

2,038

Participants

Timeline

Start Date

November 30, 1991

Primary Completion Date

November 30, 1992

Study Completion Date

November 30, 1992

Conditions
Angina, UnstableAngioplasty, Transluminal, Percutaneous Coronary
Interventions
DRUG

Abciximab

0.25 mg/kg of body weight of abciximab either bolus or infusion.

DRUG

Placebo

Matching Placebo soulution either bolus or infusion.

Sponsors

Lead Sponsor

Centocor, Inc.
All Listed Sponsors
lead

Centocor, Inc.

INDUSTRY